Connect your AI

Rapid Micro Biosystems RPID AFS Securities

AFS Securities at other companies

Pacific Biosciences of CaliforniaPACB

$83.15M+14.7%

Ginkgo BioworksDNA

$40.54M+26.0%

Fulgent Genetics, Inc.FLGT

$328.29M-33.6%

Simulations PlusSLP

$29.67M—

Bio-Rad LaboratoriesBIO

——

Other financials

Income statement

Revenue$8.0M+11.1%

Gross profit$371.0K-8.2%

Operating income-$13.9M-18.8%

Net income-$14.3M-26.7%

EPS (diluted)-$0.31-19.2%

Balance sheet

Cash & equivalents$14.1M-26.8%

Total debt$23.8M+301%

Total equity$20.4M-68.9%

Total assets$62.4M-27.0%

Cash flow

Operating cash flow-$15.1M-66.1%

CapEx$394.0K+23.5%

Free cash flow-$15.5M-64.7%

Valuation

Market cap$86.19M-43.8%

Enterprise value$95.86M-31.7%

P/S2.5×-2.6×

Profitability

Operating margin-144.2%-12.7pp

Net margin-145.8%-5.0pp

FCF margin-110.5%-14.9pp

Returns & leverage

Return on equity-116.7%-620pp

Debt / equity1.2×+1.1×

Current ratio2.6×-2.0×

Where this comes from

Reported directly by Rapid Micro Biosystems in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Rapid Micro Biosystems's AFS securities?: Rapid Micro Biosystems (RPID) reported AFS securities of $9.14M in Q1 2026.
How has Rapid Micro Biosystems's AFS securities changed year-over-year?: Rapid Micro Biosystems's AFS securities decreased by 59.8% year-over-year, from $22.75M to $9.14M.
What is the long-term trend for Rapid Micro Biosystems's AFS securities?: Over 4 years (2021 to 2025), Rapid Micro Biosystems's AFS securities has grown at a 16.3% compound annual growth rate (CAGR), from $9.97M to $18.26M.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.